A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer

Kerr, L., Rewhorn, M. J., Longmuir, M., Fraser, S., Walsh, S., Andrew, N. and Leung, H. Y. (2016) A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer. BMC Cancer, 16, 529. (doi: 10.1186/s12885-016-2573-x) (PMID:27456091) (PMCID:PMC4960816)

[img]
Preview
Text
116756.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Background: Prostate cancer (PC) is a major health concern for men worldwide, with an estimated lifetime risk of ~14 %. A recent comprehensive analysis of mutational processes revealed ageing and mismatch repair as the only altered processes in PC. We wish to test if a cohort of men with inherited risk of mismatch repair defect through BRCA1/2 or Lynch Syndrome mutations represents a target population for prostate cancer testing. Methods: Fifty-eight men (aged 40–69 years) from families with a history of BRCA1/2 or HNPCC/Lynch mutations were invited to take part. Men with PSA >3.0 ng/ml were recommended to have transrectal ultrasound-guided prostatic biopsies. Results: Overall 1 of 7 (14 %) and 1 of 20 (5 %) men with BRCA1/2 mutations were positive for a diagnosis of prostate cancer. In men with Lynch syndrome, 1 of 4 (25 %) was diagnosed to have prostate cancer. The index case with Lynch syndrome harbours a heterozygous mutation in the mismatch repair MSH6 gene. Near to complete loss of MSH6 immunoreactivity in the prostate tumour supports silencing of the remaining MSH6 allele during prostate carcinogenesis. Conclusion: The finding of near-to-complete loss of MSH6 expression in affected men with a family history of Lynch Syndrome supports its mechanistic involvement during prostate carcinogenesis. This work therefore contributes to the argument that, in certain male populations, Lynch Syndrome mutations are biologically implicated in men with prostate cancer.

Item Type:Articles
Additional Information:Hing Leung receives research funding from Cancer Research UK (A15151).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Leung, Professor Hing and Fraser, Dr Sioban
Authors: Kerr, L., Rewhorn, M. J., Longmuir, M., Fraser, S., Walsh, S., Andrew, N., and Leung, H. Y.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:BMC Cancer
Publisher:BioMed Central
ISSN:1471-2407
ISSN (Online):1471-2407
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in BMC Cancer 16: 529
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record